Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Regeneron Pharmaceuticals
REGNHealthcareGenerated Aug 20, 2026, 11:14 PM UTC
REGN (Regeneron Pharmaceuticals) analytical snapshot. Revenue grew +1.0% YoY to $14.34B. 5-year revenue CAGR -2.3%; 10y CAGR +12.8%. Net margin at 31.41% (contracting ▼). Market cap $77.67B at $826.64 per share. Trailing P/E 19.93, P/S 5.42, P/B 2.45. EV/Operating income ≈ 21.58 (EV $77.20B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score 9 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 4, 2026. Latest quarterly report (10-Q) filed Jul 30, 2026. 14 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 4, 2026.
- Latest quarterly report (10-Q) filed Jul 30, 2026.
- 14 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
| Date | Form | Description |
|---|---|---|
| Jul 30, 2026 | 8-K | 8-K |
| Jul 6, 2026 | 8-K | FORM 8-K |
| Jun 17, 2026 | 8-K | FORM 8-K |
| Apr 29, 2026 | 8-K | 8-K |
| Apr 8, 2026 | 8-K | FORM 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Jan 12, 2026 | 8-K | FORM 8-K |
| Oct 28, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
No significant implicit signals detected. Key metrics are changing within normal ranges.
- Endogenous analysis: No significant implicit signals detected in the latest filing. Key metrics are changing within normal ranges — the filing appears consistent with prior-period patterns.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $14.20B | $14.34B | $140.9M | +1.0% |
| Operating income | $3.99B | $3.58B | $-412.8M | -10.3% |
| Net income | $4.41B | $4.50B | $92.3M | +2.1% |
| Operating cash flow | $4.42B | $4.98B | $558.4M | +12.6% |
| Capex | $755.9M | $898.4M | $142.5M | +18.9% |
| Total assets | $37.76B | $40.56B | $2.80B | +7.4% |
| Total liabilities | $8.41B | $9.30B | $896.0M | +10.7% |
| Long-term debt | $1.98B | $1.99B | $1.5M | +0.1% |
| Cash & equivalents | $2.49B | $3.12B | $629.9M | +25.3% |
| Stockholders equity | $29.35B | $31.26B | $1.90B | +6.5% |
| Inventory | $3.09B | $3.20B | $113.5M | +3.7% |
| Accounts receivable | $6.21B | $5.74B | $-470.8M | -7.6% |
| R&D expense | $5.13B | $5.85B | $718.2M | +14.0% |
| SG&A expense | $2.95B | $2.70B | $-254.4M | -8.6% |
| Interest expense | $59.4M | $73.0M | $13.6M | +22.9% |
| Type | Concepts |
|---|---|
| Added | FinanceLeaseLiabilityCurrent |
| Removed | AccountsPayableAndAccruedLiabilitiesCurrent, AmortizationOfIntangibleAssets, BusinessCombinationContingentConsiderationLiability, CommonStockDividendsPerShareCashPaid, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger, DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Related party transactions | low | 1 | 0 | NEW |
Fundamentals
Revenue grew +1.0% YoY to $14.34B. 5-year revenue CAGR -2.3%; 10y CAGR +12.8%. Net margin at 31.41% (contracting ▼).
- Revenue grew +1.0% YoY to $14.34B.
- 5-year revenue CAGR -2.3%; 10y CAGR +12.8%.
- Net margin at 31.41% (contracting ▼).
- Return on equity 14.41%, ROA 11.11%, ROIC 10.76%.
- Gross margin 0.00%, operating margin 24.95%.
- Free cash flow margin 28.45% ($4.08B).
- Net income up ▲ +2.1% YoY.
- Debt/equity 0.06, current ratio 3.34, net debt -$469.2M.
- Asset turnover 0.34 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $14.20B | +8.3% | 0.00 | 28.10 | 31.07 | $3.66B | 15.03 |
| 2025 | $14.34B | +1.0% | 0.00 | 24.95 | 31.41 | $4.08B | 14.41 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jun 30, 2016 | $1.21B | +21.4% | — | 16.18% |
| Sep 30, 2016 | $1.22B | +7.3% | +0.6% | 21.70% |
| Mar 31, 2017 | $1.32B | +9.8% | +8.1% | 18.87% |
| Jun 30, 2017 | $1.47B | +21.2% | +11.5% | 26.38% |
| Sep 30, 2017 | $1.50B | +23.0% | +2.1% | 25.88% |
| Mar 31, 2018 | $1.51B | +14.6% | +0.7% | 31.62% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $77.67B at $826.64 per share. Trailing P/E 19.93, P/S 5.42, P/B 2.45. EV/Operating income ≈ 21.58 (EV $77.20B).
- Market cap $77.67B at $826.64 per share.
Price & Technicals
Price $826.64 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 80.71 (overbought).
- Price $826.64 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.65%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Low. Leverage debt/equity 0.06 (low). Liquidity current ratio 3.34 (adequate).
- Composite risk: Low.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 9
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Regeneron Pharmaceuticals is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewPrice $826.64 — uptrend (above 200-DMA); 1-month momentum positive..
Peer comparison
Defensive groupHow REGN stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| Gilead Sciences GILD | 9 | Neutral |
| Regeneron Pharmaceuticals REGN● you | 9 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Biogen Inc. BIIB | 6 | Neutral |
| Vertex Pharmaceuticals VRTX | 5 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| AbbVie Inc. ABBV | -8 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT | -8 | Neutral |
| Cigna Group CI | -9 | Neutral |
| Amgen Inc. AMGN | -9 | Neutral |
| Procter & Gamble PG | -10 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Pfizer Inc. PFE | -13 | Neutral |
| Kroger Co. KR | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |